메뉴 건너뛰기




Volumn 114, Issue 3, 2015, Pages 519-529

The influence of low-grade inflammation on platelets in patients with stable coronary artery disease

Author keywords

Antiplatelet therapy; Coronary artery disease; Inflammation; Platelet aggregation; Platelet production

Indexed keywords

C REACTIVE PROTEIN; CD40 ANTIGEN; COPEPTIN; CYCLOOXYGENASE 1; FIBRINOGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; RANTES; SPHINGOSINE 1 PHOSPHATE; THROMBOXANE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; AUTACOID; BIOLOGICAL MARKER;

EID: 84940655004     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-12-1007     Document Type: Article
Times cited : (31)

References (152)
  • 1
    • 84871036375 scopus 로고    scopus 로고
    • Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010
    • Lozano R, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095–2128
    • (2012) Lancet , vol.380 , pp. 2095-2128
    • Lozano, R.1
  • 2
    • 84865485915 scopus 로고    scopus 로고
    • Inflammation in atherosclerosis
    • Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32: 2045–2051
    • (2012) Arterioscler Thromb Vasc Biol , vol.32 , pp. 2045-2051
    • Libby, P.1
  • 3
    • 84895860734 scopus 로고    scopus 로고
    • Inflammatory cytokines and risk of coronary heart disease: New prospective study and updated meta-analysis
    • Kaptoge S, et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J 2014; 35: 578–589
    • (2014) Eur Heart J , vol.35 , pp. 578-589
    • Kaptoge, S.1
  • 4
    • 85027927298 scopus 로고    scopus 로고
    • Role of Vascular Inflammation in Coronary Artery Disease: Potential of Anti-inflammatory Drugs in the Prevention of Atherothrombosis: Inflammation and Anti-Inflammatory Drugs in Coronary Artery Disease
    • Moreira DM, et al. Role of Vascular Inflammation in Coronary Artery Disease: Potential of Anti-inflammatory Drugs in the Prevention of Atherothrombosis: Inflammation and Anti-Inflammatory Drugs in Coronary Artery Disease. Am J Cardiovasc Drugs 2015; 15: 1–11
    • (2015) Am J Cardiovasc Drugs , vol.15 , pp. 1-11
    • Moreira, D.M.1
  • 5
    • 37249068049 scopus 로고    scopus 로고
    • Platelet activation and atherothrombosis
    • Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482–2494
    • (2007) N Engl J Med , vol.357 , pp. 2482-2494
    • Davi, G.1    Patrono, C.2
  • 6
    • 84896702904 scopus 로고    scopus 로고
    • Targeting inflammation: Impact on atherothrombosis
    • Marini MG, et al. Targeting inflammation: impact on atherothrombosis. J Cardiovasc Transl Res 2014; 7: 9–18
    • (2014) J Cardiovasc Transl Res , vol.7 , pp. 9-18
    • Marini, M.G.1
  • 7
    • 84904116778 scopus 로고    scopus 로고
    • Clinical usefulness of novel serum and imaging biomarkers in risk stratification of patients with stable angina
    • Tsaknis G, et al. Clinical usefulness of novel serum and imaging biomarkers in risk stratification of patients with stable angina. Dis Markers 2014; 2014: 831364
    • (2014) Dis Markers , vol.2014
    • Tsaknis, G.1
  • 8
    • 77956398698 scopus 로고    scopus 로고
    • C-reactive protein is a mediator of cardiovascular disease
    • Bisoendial RJ, et al. C-reactive protein is a mediator of cardiovascular disease. Eur Heart J 2010; 31: 2087–2091
    • (2010) Eur Heart J , vol.31 , pp. 2087-2091
    • Bisoendial, R.J.1
  • 9
    • 73449130797 scopus 로고    scopus 로고
    • C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis
    • Kaptoge S, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375: 132–140
    • (2010) Lancet , vol.375 , pp. 132-140
    • Kaptoge, S.1
  • 10
    • 57749210419 scopus 로고    scopus 로고
    • C-reactive protein and parental history improve global cardiovascular risk prediction: The Reynolds Risk Score for men
    • Ridker PM, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008; 118: 2243–2251
    • (2008) Circulation , vol.118 , pp. 2243-2251
    • Ridker, P.M.1
  • 11
    • 67349274128 scopus 로고    scopus 로고
    • Predictive value of coronary artery stenoses and C-reactive protein levels in patients with stable coronary artery disease
    • Arroyo-Espliguero R, et al. Predictive value of coronary artery stenoses and C-reactive protein levels in patients with stable coronary artery disease. Atherosclerosis 2009; 204: 239–243
    • (2009) Atherosclerosis , vol.204 , pp. 239-243
    • Arroyo-Espliguero, R.1
  • 12
    • 34247477664 scopus 로고    scopus 로고
    • Prognostic significance of the Centers for Disease Control/ American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease
    • Sabatine MS, et al. Prognostic significance of the Centers for Disease Control/ American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007; 115: 1528–1536
    • (2007) Circulation , vol.115 , pp. 1528-1536
    • Sabatine, M.S.1
  • 13
    • 0037081679 scopus 로고    scopus 로고
    • Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction
    • Zebrack JS, et al. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol 2002; 89: 145–149
    • (2002) Am J Cardiol , vol.89 , pp. 145-149
    • Zebrack, J.S.1
  • 14
    • 0033596685 scopus 로고    scopus 로고
    • Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability
    • Biasucci LM, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99: 855–860
    • (1999) Circulation , vol.99 , pp. 855-860
    • Biasucci, L.M.1
  • 15
    • 0027933081 scopus 로고
    • The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina
    • Liuzzo G, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 417–424
    • (1994) N Engl J Med , vol.331 , pp. 417-424
    • Liuzzo, G.1
  • 16
    • 38349084093 scopus 로고    scopus 로고
    • Independent prognostic value of C-reactive protein and coronary artery disease extent in patients affected by unstable angina
    • Niccoli G, et al. Independent prognostic value of C-reactive protein and coronary artery disease extent in patients affected by unstable angina. Atherosclerosis 2008; 196: 779–785
    • (2008) Atherosclerosis , vol.196 , pp. 779-785
    • Niccoli, G.1
  • 17
    • 0031054058 scopus 로고    scopus 로고
    • Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group
    • Haverkate F, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349: 462–466
    • (1997) Lancet , vol.349 , pp. 462-466
    • Haverkate, F.1
  • 18
    • 55249087635 scopus 로고    scopus 로고
    • Genetically elevated C-reactive protein and ischemic vascular disease
    • Zacho J, et al. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008; 359: 1897–1908
    • (2008) N Engl J Med , vol.359 , pp. 1897-1908
    • Zacho, J.1
  • 19
    • 0037469232 scopus 로고    scopus 로고
    • Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association
    • Pearson TA, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499–511
    • (2003) Circulation , vol.107 , pp. 499-511
    • Pearson, T.A.1
  • 20
    • 0037138517 scopus 로고    scopus 로고
    • C-reactive protein and angiographic coronary artery disease: Independent and additive predictors of risk in subjects with angina
    • Zebrack JS, et al. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol 2002; 39: 632–637
    • (2002) J am Coll Cardiol , vol.39 , pp. 632-637
    • Zebrack, J.S.1
  • 21
    • 84908380639 scopus 로고    scopus 로고
    • Relation of C-Reactive Protein to Coronary Plaque Characteristics on Grayscale, Radiofrequency Intravascular Ultrasound, and Cardiovascular Outcome in Patients With Acute Coronary Syndrome or Stable Angina Pectoris (From the ATHEROREMO-IVUS Study)
    • Cheng JM, et al. Relation of C-Reactive Protein to Coronary Plaque Characteristics on Grayscale, Radiofrequency Intravascular Ultrasound, and Cardiovascular Outcome in Patients With Acute Coronary Syndrome or Stable Angina Pectoris (from the ATHEROREMO-IVUS Study). Am J Cardiol 2014; 114: 1497–1503
    • (2014) Am J Cardiol , vol.114 , pp. 1497-1503
    • Cheng, J.M.1
  • 22
    • 74249093153 scopus 로고    scopus 로고
    • High-sensitivity C-reactive protein and plaque composition in patients with stable angina pectoris: A virtual histology intravascular ultrasound study
    • Kubo T, et al. High-sensitivity C-reactive protein and plaque composition in patients with stable angina pectoris: a virtual histology intravascular ultrasound study. Coron Artery Dis 2009; 20: 531–535
    • (2009) Coron Artery Dis , vol.20 , pp. 531-535
    • Kubo, T.1
  • 23
    • 84862119222 scopus 로고    scopus 로고
    • European Guidelines on cardiovascular disease prevention in clinical practice (Version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)
    • Perk J, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635–1701
    • (2012) Eur Heart J , vol.33 , pp. 1635-1701
    • Perk, J.1
  • 24
    • 79960996780 scopus 로고    scopus 로고
    • Inflammation and thrombosis in diabetes
    • Hess K, Grant PJ. Inflammation and thrombosis in diabetes. Thromb Haemost 2011; 105 (Suppl 1): S43-S54
    • (2011) Thromb Haemost , vol.105
    • Hess, K.1    Grant, P.J.2
  • 25
    • 0037395239 scopus 로고    scopus 로고
    • Fibrin(Ogen) in cardiovascular disease: An update
    • Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 2003; 89: 601–609
    • (2003) Thromb Haemost , vol.89 , pp. 601-609
    • Koenig, W.1
  • 26
    • 0032513756 scopus 로고    scopus 로고
    • Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies
    • Danesh J, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. J Am Med Assoc 1998; 279: 1477–1482
    • (1998) J am Med Assoc , vol.279 , pp. 1477-1482
    • Danesh, J.1
  • 27
    • 84897925216 scopus 로고    scopus 로고
    • Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure
    • Neergaard-Petersen S, et al. Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure. PLoS One 2013; 8: e71150
    • (2013) Plos One , vol.8
    • Neergaard-Petersen, S.1
  • 28
    • 84914109016 scopus 로고    scopus 로고
    • The influence of type 2 diabetes on fibrin clot properties in patients with CAD
    • Neergaard-Petersen S, et al. The influence of type 2 diabetes on fibrin clot properties in patients with CAD. Thromb Haemost 2014; 112: 1142–1150
    • (2014) Thromb Haemost , vol.112 , pp. 1142-1150
    • Neergaard-Petersen, S.1
  • 29
    • 28344452909 scopus 로고    scopus 로고
    • Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease
    • Lowe GD. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost 2005; 3: 1618–1627
    • (2005) J Thromb Haemost , vol.3 , pp. 1618-1627
    • Lowe, G.D.1
  • 30
    • 0025190892 scopus 로고
    • Interleukin-6 and the acute phase response
    • Heinrich PC, et al. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621–636
    • (1990) Biochem J , vol.265 , pp. 621-636
    • Heinrich, P.C.1
  • 31
    • 0024423176 scopus 로고
    • Adult human vascular endothelial cells express the IL6 gene differentially in response to LPS or IL1
    • Loppnow H, Libby P. Adult human vascular endothelial cells express the IL6 gene differentially in response to LPS or IL1. Cell Immunol 1989; 122: 493–503
    • (1989) Cell Immunol , vol.122 , pp. 493-503
    • Loppnow, H.1    Libby, P.2
  • 32
    • 0028261395 scopus 로고
    • Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions
    • Seino Y, et al. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine 1994; 6: 87–91
    • (1994) Cytokine , vol.6 , pp. 87-91
    • Seino, Y.1
  • 33
    • 0034681920 scopus 로고    scopus 로고
    • Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men
    • Ridker PM, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767–1772
    • (2000) Circulation , vol.101 , pp. 1767-1772
    • Ridker, P.M.1
  • 34
    • 0035916309 scopus 로고    scopus 로고
    • Cardiovascular disease, interleukin-6, and risk of mortality in older women: The women’s health and aging study
    • Volpato S, et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women’s health and aging study. Circulation 2001; 103: 947–953
    • (2001) Circulation , vol.103 , pp. 947-953
    • Volpato, S.1
  • 35
    • 0033134682 scopus 로고    scopus 로고
    • Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly
    • Harris TB, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106: 506–512
    • (1999) Am J Med , vol.106 , pp. 506-512
    • Harris, T.B.1
  • 36
    • 0034759210 scopus 로고    scopus 로고
    • Interleukin-6 and acute coronary syndrome
    • Ikeda U, et al. Interleukin-6 and acute coronary syndrome. Clin Cardiol 2001; 24: 701–704
    • (2001) Clin Cardiol , vol.24 , pp. 701-704
    • Ikeda, U.1
  • 37
    • 84902360138 scopus 로고    scopus 로고
    • Correlation of serum high-sensitivity C-reactive protein and interleukin- 6 in patients with acute coronary syndrome
    • Wang XH, et al. Correlation of serum high-sensitivity C-reactive protein and interleukin- 6 in patients with acute coronary syndrome. Genet Mol Res 2014; 13: 4260–4266
    • (2014) Genet Mol Res , vol.13 , pp. 4260-4266
    • Wang, X.H.1
  • 38
    • 84859424082 scopus 로고    scopus 로고
    • Subacute inflammatory activation in subjects with acute coronary syndrome and left ventricular dysfunction
    • De Gennaro L, et al. Subacute inflammatory activation in subjects with acute coronary syndrome and left ventricular dysfunction. Inflammation 2012; 35: 363–370
    • (2012) Inflammation , vol.35 , pp. 363-370
    • De Gennaro, L.1
  • 39
    • 80051957023 scopus 로고    scopus 로고
    • Relationship between coronary atherosclerosis plaque characteristics and high sensitivity C-reactive proteins, interleukin-6
    • Lai CL, et al. Relationship between coronary atherosclerosis plaque characteristics and high sensitivity C-reactive proteins, interleukin-6. Chin Med J 2011; 124: 2452–2456
    • (2011) Chin Med J , vol.124 , pp. 2452-2456
    • Lai, C.L.1
  • 40
    • 0032773905 scopus 로고    scopus 로고
    • Plasma levels of interleukin 2, 6, 10 and phenotypic characterisation of circulating T lymphocytes in ischemic heart disease
    • Mazzone A, et al. Plasma levels of interleukin 2, 6, 10 and phenotypic characterisation of circulating T lymphocytes in ischemic heart disease. Atherosclerosis 1999; 145: 369–374
    • (1999) Atherosclerosis , vol.145 , pp. 369-374
    • Mazzone, A.1
  • 41
    • 33745145788 scopus 로고    scopus 로고
    • Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction
    • Fisman EZ, et al. Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction. Am J Cardiol 2006; 98: 14–18
    • (2006) Am J Cardiol , vol.98 , pp. 14-18
    • Fisman, E.Z.1
  • 42
    • 14144249221 scopus 로고    scopus 로고
    • Prognostic value of inflammatory markers alone and in combination with blood lipids in patients with stable coronary artery disease
    • Hoffmeister A, et al. Prognostic value of inflammatory markers alone and in combination with blood lipids in patients with stable coronary artery disease. Eur J Intern Med 2005; 16: 47–52
    • (2005) Eur J Intern Med , vol.16 , pp. 47-52
    • Hoffmeister, A.1
  • 43
    • 84906509517 scopus 로고    scopus 로고
    • Platelets and their chemokines in atherosclerosis- clinical applications
    • von Hundelshausen P, Schmitt MM. Platelets and their chemokines in atherosclerosis- clinical applications. Front Physiol 2014; 5: 294
    • (2014) Front Physiol , vol.5
    • Von Hundelshausen, P.1    Schmitt, M.M.2
  • 44
    • 63349086636 scopus 로고    scopus 로고
    • Expression of stromal-cell-derived factor-1 on circulating platelets is increased in patients with acute coronary syndrome and correlates with the number of CD34+ progenitor cells
    • Stellos K, et al. Expression of stromal-cell-derived factor-1 on circulating platelets is increased in patients with acute coronary syndrome and correlates with the number of CD34+ progenitor cells. Eur Heart J 2009; 30: 584–593
    • (2009) Eur Heart J , vol.30 , pp. 584-593
    • Stellos, K.1
  • 45
    • 38049113170 scopus 로고    scopus 로고
    • Platelet-derived stromal cell-derived factor-1 regulates adhesion and promotes differentiation of human CD34+ cells to endothelial progenitor cells
    • Stellos K, et al. Platelet-derived stromal cell-derived factor-1 regulates adhesion and promotes differentiation of human CD34+ cells to endothelial progenitor cells. Circulation 2008; 117: 206–215
    • (2008) Circulation , vol.117 , pp. 206-215
    • Stellos, K.1
  • 46
    • 84875211343 scopus 로고    scopus 로고
    • Platelet expression of stromal-cell-derived factor-1 (SDF-1): An indicator for ACS?
    • Wurster T, et al. Platelet expression of stromal-cell-derived factor-1 (SDF-1): an indicator for ACS? Int J Cardiol 2013; 164: 111–115
    • (2013) Int J Cardiol , vol.164 , pp. 111-115
    • Wurster, T.1
  • 47
    • 84858282426 scopus 로고    scopus 로고
    • Association of platelet-SDF-1 with hemodynamic function and infarct size using cardiac MR in patients with AMI
    • Geisler T, et al. Association of platelet-SDF-1 with hemodynamic function and infarct size using cardiac MR in patients with AMI. Eur J Radiol 2012; 81: e486-e490
    • (2012) Eur J Radiol , vol.81
    • Geisler, T.1
  • 48
    • 84928757801 scopus 로고    scopus 로고
    • Platelet surface expression of SDF-1 receptors CXCR4 and CXCR7 is associated with clinical outcomes in patients with coronary artery disease
    • In press
    • Rath D, et al. Platelet surface expression of SDF-1 receptors CXCR4 and CXCR7 is associated with clinical outcomes in patients with coronary artery disease. J Thromb Haemost 2015; In press.
    • (2015) J Thromb Haemost
    • Rath, D.1
  • 49
    • 41249096995 scopus 로고    scopus 로고
    • CXCL16/SR-PSOX--a friend or a foe in atherosclerosis?
    • Sheikine Y, Sirsjo A. CXCL16/SR-PSOX--a friend or a foe in atherosclerosis? Atherosclerosis 2008; 197: 487–495
    • (2008) Atherosclerosis , vol.197 , pp. 487-495
    • Sheikine, Y.1    Sirsjo, A.2
  • 50
    • 79953742939 scopus 로고    scopus 로고
    • The CXCL16 A181V mutation selectively inhibits monocyte adhesion to CXCR6 but is not associated with human coronary heart disease
    • Petit SJ, et al. The CXCL16 A181V mutation selectively inhibits monocyte adhesion to CXCR6 but is not associated with human coronary heart disease. Arterioscler Thromb Vasc Biol 2011; 31: 914–920
    • (2011) Arterioscler Thromb Vasc Biol , vol.31 , pp. 914-920
    • Petit, S.J.1
  • 51
    • 33846367727 scopus 로고    scopus 로고
    • CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans
    • Lehrke M, et al. CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. J Am Coll Cardiol 2007; 49: 442–449
    • (2007) J am Coll Cardiol , vol.49 , pp. 442-449
    • Lehrke, M.1
  • 52
    • 73249121864 scopus 로고    scopus 로고
    • Circulating soluble SR-PSOX/CXCL16 as a biomarker for acute coronary syndrome -comparison with high-sensitivity C-reactive protein
    • Mitsuoka H, et al. Circulating soluble SR-PSOX/CXCL16 as a biomarker for acute coronary syndrome -comparison with high-sensitivity C-reactive protein. J Atheroscler Thromb 2009; 16: 586–593
    • (2009) J Atheroscler Thromb , vol.16 , pp. 586-593
    • Mitsuoka, H.1
  • 53
    • 67650767016 scopus 로고    scopus 로고
    • Soluble CXCL16 predicts long-term mortality in acute coronary syndromes
    • Jansson AM, et al. Soluble CXCL16 predicts long-term mortality in acute coronary syndromes. Circulation 2009; 119: 3181–3188
    • (2009) Circulation , vol.119 , pp. 3181-3188
    • Jansson, A.M.1
  • 54
    • 84904413140 scopus 로고    scopus 로고
    • The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease
    • Doring Y, et al. The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease. Front Physiol 2014; 5: 212
    • (2014) Front Physiol , vol.5
    • Doring, Y.1
  • 55
    • 34249066942 scopus 로고    scopus 로고
    • MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment
    • Bernhagen J, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007; 13: 587–596
    • (2007) Nat Med , vol.13 , pp. 587-596
    • Bernhagen, J.1
  • 56
    • 46149085746 scopus 로고    scopus 로고
    • Macrophage migration inhibitory factor (MIF) and risk for coronary heart disease: Results from the MONICA/KORA Augsburg case-cohort study, 1984–2002
    • Herder C, et al. Macrophage migration inhibitory factor (MIF) and risk for coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. Atherosclerosis 2008; 200: 380–388
    • (2008) Atherosclerosis , vol.200 , pp. 380-388
    • Herder, C.1
  • 57
    • 5444227083 scopus 로고    scopus 로고
    • Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: The EPIC-Norfolk Prospective Population study
    • Boekholdt SM, et al. Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: the EPIC-Norfolk Prospective Population study. Am J Med 2004; 117: 390–397
    • (2004) Am J Med , vol.117 , pp. 390-397
    • Boekholdt, S.M.1
  • 58
    • 84908674396 scopus 로고    scopus 로고
    • Impact of counterbalance between macrophage migration inhibitory factor and its inhibitor Gremlin-1 in patients with coronary artery disease
    • Muller II, et al. Impact of counterbalance between macrophage migration inhibitory factor and its inhibitor Gremlin-1 in patients with coronary artery disease. Atherosclerosis 2014; 237: 426–432
    • (2014) Atherosclerosis , vol.237 , pp. 426-432
    • Muller, I.I.1
  • 59
    • 84872754527 scopus 로고    scopus 로고
    • Macrophage migration inhibitory factor is enhanced in acute coronary syndromes and is associated with the inflammatory response
    • Muller II, et al. Macrophage migration inhibitory factor is enhanced in acute coronary syndromes and is associated with the inflammatory response. PLoS One 2012; 7: e38376
    • (2012) Plos One , vol.7
    • Muller, I.I.1
  • 60
    • 78649757640 scopus 로고    scopus 로고
    • High plasma levels of macrophage migration inhibitory factor are associated with adverse long-term outcome in patients with stable coronary artery disease and impaired glucose tolerance or type 2 diabetes mellitus
    • Makino A, et al. High plasma levels of macrophage migration inhibitory factor are associated with adverse long-term outcome in patients with stable coronary artery disease and impaired glucose tolerance or type 2 diabetes mellitus. Atherosclerosis 2010; 213: 573–578
    • (2010) Atherosclerosis , vol.213 , pp. 573-578
    • Makino, A.1
  • 61
    • 0141996919 scopus 로고    scopus 로고
    • Platelet chemokines and chemokine receptors: Linking hemostasis, inflammation, and host defense
    • Gear AR, Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation 2003; 10: 335–350
    • (2003) Microcirculation , vol.10 , pp. 335-350
    • Gear, A.R.1    Camerini, D.2
  • 62
    • 1042291188 scopus 로고    scopus 로고
    • Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice
    • Veillard NR, et al. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 2004; 94: 253–261
    • (2004) Circ Res , vol.94 , pp. 253-261
    • Veillard, N.R.1
  • 63
    • 0035799376 scopus 로고    scopus 로고
    • RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium
    • von Hundelshausen P, et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001; 103: 1772–1777
    • (2001) Circulation , vol.103 , pp. 1772-1777
    • Von Hundelshausen, P.1
  • 64
    • 0037126048 scopus 로고    scopus 로고
    • Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury
    • Schober A, et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002; 106: 1523–1529
    • (2002) Circulation , vol.106 , pp. 1523-1529
    • Schober, A.1
  • 65
    • 37349016235 scopus 로고    scopus 로고
    • CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms
    • Kraaijeveld AO, et al. CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms. Circulation 2007; 116: 1931–1941
    • (2007) Circulation , vol.116 , pp. 1931-1941
    • Kraaijeveld, A.O.1
  • 66
    • 33644823999 scopus 로고    scopus 로고
    • Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers
    • Rothenbacher D, et al. Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. Arterioscler Thromb Vasc Biol 2006; 26: 194–199
    • (2006) Arterioscler Thromb Vasc Biol , vol.26 , pp. 194-199
    • Rothenbacher, D.1
  • 67
    • 84866709173 scopus 로고    scopus 로고
    • Chemokines CCL3/MIP1alpha, CCL5/RANTES and CCL18/PARC are independent risk predictors of short-term mortality in patients with acute coronary syndromes
    • de Jager SC, et al. Chemokines CCL3/MIP1alpha, CCL5/RANTES and CCL18/PARC are independent risk predictors of short-term mortality in patients with acute coronary syndromes. PLoS One 2012; 7: e45804
    • (2012) Plos One , vol.7
    • De Jager, S.C.1
  • 68
    • 84880505530 scopus 로고    scopus 로고
    • RANTES/CCL5 and risk for coronary events: Results from the MONICA/KORA Augsburg case-cohort, Athero-Express and CARDIoGRAM studies
    • Herder C, et al. RANTES/CCL5 and risk for coronary events: results from the MONICA/KORA Augsburg case-cohort, Athero-Express and CARDIoGRAM studies. PLoS One 2011; 6: e25734
    • (2011) Plos One , vol.6
    • Herder, C.1
  • 69
    • 34247191631 scopus 로고    scopus 로고
    • Low plasma RANTES levels are an independent predictor of cardiac mortality in patients referred for coronary angiography
    • Cavusoglu E, et al. Low plasma RANTES levels are an independent predictor of cardiac mortality in patients referred for coronary angiography. Arterioscler Thromb Vasc Biol 2007; 27: 929–935
    • (2007) Arterioscler Thromb Vasc Biol , vol.27 , pp. 929-935
    • Cavusoglu, E.1
  • 70
    • 26244457957 scopus 로고    scopus 로고
    • RANTES gene polymorphisms predict all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients
    • Boger CA, et al. RANTES gene polymorphisms predict all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients. Atherosclerosis 2005; 183: 121–129
    • (2005) Atherosclerosis , vol.183 , pp. 121-129
    • Boger, C.A.1
  • 71
    • 0025900907 scopus 로고
    • Identification of p8, 14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells
    • Edgeworth J, et al. Identification of p8, 14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. J Biol Chem 1991; 266: 7706–7713
    • (1991) J Biol Chem , vol.266 , pp. 7706-7713
    • Edgeworth, J.1
  • 72
    • 44849140775 scopus 로고    scopus 로고
    • Monomeric calgranulins measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis
    • de Seny D, et al. Monomeric calgranulins measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis. Clin Chem 2008; 54: 1066–1075
    • (2008) Clin Chem , vol.54 , pp. 1066-1075
    • De Seny, D.1
  • 73
    • 61949096973 scopus 로고    scopus 로고
    • Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis
    • Ho GT, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol 2009; 104: 673–678
    • (2009) Am J Gastroenterol , vol.104 , pp. 673-678
    • Ho, G.T.1
  • 74
    • 36849078292 scopus 로고    scopus 로고
    • Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial
    • Morrow DA, et al. Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J 2008; 155: 49–55
    • (2008) Am Heart J , vol.155 , pp. 49-55
    • Morrow, D.A.1
  • 75
    • 33744997382 scopus 로고    scopus 로고
    • Platelet expression profiling and clinical validation of myeloidrelated protein-14 as a novel determinant of cardiovascular events
    • Healy AM, et al. Platelet expression profiling and clinical validation of myeloidrelated protein-14 as a novel determinant of cardiovascular events. Circulation 2006; 113: 2278–2284
    • (2006) Circulation , vol.113 , pp. 2278-2284
    • Healy, A.M.1
  • 76
    • 34548316925 scopus 로고    scopus 로고
    • Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: A novel, early, and sensitive marker of acute coronary syndromes
    • Altwegg LA, et al. Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. Eur Heart J 2007; 28: 941–948
    • (2007) Eur Heart J , vol.28 , pp. 941-948
    • Altwegg, L.A.1
  • 77
    • 84891751136 scopus 로고    scopus 로고
    • Plasma S100A8/A9 Correlates With Blood Neutrophil Counts, Traditional Risk Factors, and Cardiovascular Disease in Middle-Aged Healthy Individuals
    • Cotoi OS, et al. Plasma S100A8/A9 Correlates With Blood Neutrophil Counts, Traditional Risk Factors, and Cardiovascular Disease in Middle-Aged Healthy Individuals. Arterioscler Thromb Vasc Biol 2014; 34: 202–210
    • (2014) Arterioscler Thromb Vasc Biol , vol.34 , pp. 202-210
    • Cotoi, O.S.1
  • 78
    • 84929326427 scopus 로고    scopus 로고
    • Calprotectin and platelet aggregation in patients with stable coronary artery disease
    • In press
    • Larsen SB, et al. Calprotectin and platelet aggregation in patients with stable coronary artery disease. PLoS One 2015; In press.
    • (2015) Plos One
    • Larsen, S.B.1
  • 79
    • 84929141828 scopus 로고    scopus 로고
    • Circulating myeloid-related protein-8/14 is related to thromboxane- dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment
    • Epub ahead of print
    • Santilli F, et al. Circulating myeloid-related protein-8/14 is related to thromboxane- dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment. J Am Heart Assoc 2014; Epub ahead of print.
    • (2014) J am Heart Assoc
    • Santilli, F.1
  • 80
    • 39849083221 scopus 로고    scopus 로고
    • Copeptin: Clinical use of a new biomarker
    • Morgenthaler NG, et al. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008; 19: 43–49
    • (2008) Trends Endocrinol Metab , vol.19 , pp. 43-49
    • Morgenthaler, N.G.1
  • 81
    • 77951649887 scopus 로고    scopus 로고
    • Copeptin improves early diagnosis of acute myocardial infarction
    • Keller T, et al. Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol 2010; 55: 2096–2106
    • (2010) J am Coll Cardiol , vol.55 , pp. 2096-2106
    • Keller, T.1
  • 82
    • 66249145041 scopus 로고    scopus 로고
    • C-terminal provasopressin (Copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: Results from the OPTIMAAL study
    • Voors AA, et al. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J 2009; 30: 1187–1194
    • (2009) Eur Heart J , vol.30 , pp. 1187-1194
    • Voors, A.A.1
  • 83
    • 84870250540 scopus 로고    scopus 로고
    • Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease
    • von Haehling S, et al. Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease. Int J Cardiol 2012; 162: 27–32
    • (2012) Int J Cardiol , vol.162 , pp. 27-32
    • Von Haehling, S.1
  • 84
    • 40749151527 scopus 로고    scopus 로고
    • Platelets: Inflammatory firebugs of vascular walls
    • May AE, et al. Platelets: inflammatory firebugs of vascular walls. Arterioscler Thromb Vasc Biol 2008; 28: s5–10
    • (2008) Arterioscler Thromb Vasc Biol , vol.28
    • May, A.E.1
  • 85
    • 0033964318 scopus 로고    scopus 로고
    • The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques
    • Abi-Younes S, et al. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res 2000; 86: 131–138
    • (2000) Circ Res , vol.86 , pp. 131-138
    • Abi-Younes, S.1
  • 86
    • 0035865519 scopus 로고    scopus 로고
    • Adenosine diphosphate strongly potentiates the ability of the chemokines MDC, TARC, and SDF-1 to stimulate platelet function
    • Gear AR, et al. Adenosine diphosphate strongly potentiates the ability of the chemokines MDC, TARC, and SDF-1 to stimulate platelet function. Blood 2001; 97: 937–945
    • (2001) Blood , vol.97 , pp. 937-945
    • Gear, A.R.1
  • 87
    • 0032913869 scopus 로고    scopus 로고
    • Megakaryocyte precursors, megakaryocytes and platelets express the HIV co-receptor CXCR4 on their surface: Determination of response to stromal-derived factor-1 by megakaryocytes and platelets
    • Kowalska MA, et al. Megakaryocyte precursors, megakaryocytes and platelets express the HIV co-receptor CXCR4 on their surface: determination of response to stromal-derived factor-1 by megakaryocytes and platelets. Br J Haematol 1999; 104: 220–229
    • (1999) Br J Haematol , vol.104 , pp. 220-229
    • Kowalska, M.A.1
  • 88
    • 84903740197 scopus 로고    scopus 로고
    • SDF-1alpha induces differential trafficking of CXCR4-CXCR7 involving cyclophilin A, CXCR7 ubiquitination and promotes platelet survival
    • Chatterjee M, et al. SDF-1alpha induces differential trafficking of CXCR4-CXCR7 involving cyclophilin A, CXCR7 ubiquitination and promotes platelet survival. FASEB J 2014; 28: 2864–2878
    • (2014) FASEB J , vol.28 , pp. 2864-2878
    • Chatterjee, M.1
  • 89
    • 79958128409 scopus 로고    scopus 로고
    • CXCL16 is a novel scavenger receptor on platelets and is associated with acute coronary syndrome
    • Seizer P, et al. CXCL16 is a novel scavenger receptor on platelets and is associated with acute coronary syndrome. Thromb Haemost 2011; 105: 1112–1114
    • (2011) Thromb Haemost , vol.105 , pp. 1112-1114
    • Seizer, P.1
  • 90
    • 84868699503 scopus 로고    scopus 로고
    • The inflammatory chemokine CXC motif ligand 16 triggers platelet activation and adhesion via CXC motif receptor 6-dependent phosphatidylinositide 3-kinase/Akt signaling
    • Borst O, et al. The inflammatory chemokine CXC motif ligand 16 triggers platelet activation and adhesion via CXC motif receptor 6-dependent phosphatidylinositide 3-kinase/Akt signaling. Circ Res 2012; 111: 1297–1307
    • (2012) Circ Res , vol.111 , pp. 1297-1307
    • Borst, O.1
  • 91
    • 0037231665 scopus 로고    scopus 로고
    • Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein
    • Huo Y, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9: 61–67
    • (2003) E. Nat Med , vol.9 , pp. 61-67
    • Huo, Y.1
  • 92
    • 41649100060 scopus 로고    scopus 로고
    • Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(Hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice
    • Combadiere C, et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 2008; 117: 1649–1657
    • (2008) Circulation , vol.117 , pp. 1649-1657
    • Combadiere, C.1
  • 93
    • 84878486651 scopus 로고    scopus 로고
    • Advances in megakaryocytopoiesis and thrombopoiesis: From bench to bedside
    • Deutsch VR, Tomer A. Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside. Br J Haematol 2013; 161: 778–793
    • (2013) Br J Haematol , vol.161 , pp. 778-793
    • Deutsch, V.R.1    Tomer, A.2
  • 94
    • 0026468613 scopus 로고
    • The significance of platelets with increased RNA content (Reticulated platelets). A measure of the rate of thrombopoiesis
    • Ault KA, et al. The significance of platelets with increased RNA content (reticulated platelets). A measure of the rate of thrombopoiesis. Am J Clin Pathol 1992; 98: 637–646
    • (1992) Am J Clin Pathol , vol.98 , pp. 637-646
    • Ault, K.A.1
  • 95
    • 78650952436 scopus 로고    scopus 로고
    • Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease
    • Grove EL, et al. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011; 9: 185–191
    • (2011) J Thromb Haemost , vol.9 , pp. 185-191
    • Grove, E.L.1
  • 96
    • 84908101852 scopus 로고    scopus 로고
    • Platelet turnover in stable coronary artery disease–influence of thrombopoietin and low-grade inflammation
    • Larsen SB, et al. Platelet turnover in stable coronary artery disease–influence of thrombopoietin and low-grade inflammation. PLoS One 2014; 9: e85566
    • (2014) Plos One , vol.9
    • Larsen, S.B.1
  • 97
    • 33845224836 scopus 로고    scopus 로고
    • Thrombopoietin contributes to enhanced platelet activation in patients with unstable angina
    • Lupia E, et al. Thrombopoietin contributes to enhanced platelet activation in patients with unstable angina. J Am Coll Cardiol 2006; 48: 2195–2203
    • (2006) J am Coll Cardiol , vol.48 , pp. 2195-2203
    • Lupia, E.1
  • 98
    • 0035034873 scopus 로고    scopus 로고
    • Thrombopoietin and mean platelet volume in coronary artery disease
    • Senaran H, et al. Thrombopoietin and mean platelet volume in coronary artery disease. Clin Cardiol 2001; 24: 405–408
    • (2001) Clin Cardiol , vol.24 , pp. 405-408
    • Senaran, H.1
  • 99
    • 0001288334 scopus 로고
    • Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro
    • Ishibashi T, et al. Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proc Natl Acad Sci USA 1989; 86: 5953–5957
    • (1989) Proc Natl Acad Sci USA , vol.86 , pp. 5953-5957
    • Ishibashi, T.1
  • 100
    • 77949429612 scopus 로고    scopus 로고
    • Determinants of platelet number and regulation of thrombopoiesis
    • Kaushansky K. Determinants of platelet number and regulation of thrombopoiesis. Hematology Am Soc Hematol Educ Program 2009; 147–152
    • (2009) Hematology am Soc Hematol Educ Program , pp. 147-152
    • Kaushansky, K.1
  • 101
    • 0027893144 scopus 로고
    • Continuous infusion of interleukin-6 in sublethally irradiated mice accelerates platelet reconstitution and the recovery of myeloid but not of megakaryocytic progenitor cells in bone marrow
    • Laterveer L, et al. Continuous infusion of interleukin-6 in sublethally irradiated mice accelerates platelet reconstitution and the recovery of myeloid but not of megakaryocytic progenitor cells in bone marrow. Exp Hematol 1993; 21: 1621–1627
    • (1993) Exp Hematol , vol.21 , pp. 1621-1627
    • Laterveer, L.1
  • 102
    • 36549044972 scopus 로고    scopus 로고
    • Thrombopoietin is not uniquely responsible for thrombocytosis in inflammatory disorders
    • Ceresa IF, et al. Thrombopoietin is not uniquely responsible for thrombocytosis in inflammatory disorders. Platelets 2007; 18: 579–582
    • (2007) Platelets , vol.18 , pp. 579-582
    • Ceresa, I.F.1
  • 103
    • 84898973206 scopus 로고    scopus 로고
    • Mean Platelet Volume Associated With Aortic Distensibility, Chronic Inflammation, and Diabetes in Patients With Stable Coronary Artery Disease
    • Sahin DY, et al. Mean Platelet Volume Associated With Aortic Distensibility, Chronic Inflammation, and Diabetes in Patients With Stable Coronary Artery Disease. Clin Appl Thromb Hemost 2012; 20: 416–421
    • (2012) Clin Appl Thromb Hemost , vol.20 , pp. 416-421
    • Sahin, D.Y.1
  • 104
    • 65849268320 scopus 로고    scopus 로고
    • Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials
    • Baigent C, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–1860
    • (2009) Lancet , vol.373 , pp. 1849-1860
    • Baigent, C.1
  • 106
    • 84930672019 scopus 로고    scopus 로고
    • Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease
    • In press
    • Larsen SB, et al. Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease. PLoS One 2015;. In press.
    • (2015) Plos One
    • Larsen, S.B.1
  • 107
    • 84870047461 scopus 로고    scopus 로고
    • Interindividual variability in the efficacy of oral antiplatelet drugs: Definitions, mechanisms and clinical importance
    • Wurtz M, Grove EL. Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance. Curr Pharm Des 2012; 18: 5344–5361
    • (2012) Curr Pharm Des , vol.18 , pp. 5344-5361
    • Wurtz, M.1    Grove, E.L.2
  • 108
    • 84871616417 scopus 로고    scopus 로고
    • Vascular and platelet responses to aspirin in patients with coronary artery disease
    • Blann AD, et al. Vascular and platelet responses to aspirin in patients with coronary artery disease. Eur J Clin Invest 2013; 43: 91–99
    • (2013) Eur J Clin Invest , vol.43 , pp. 91-99
    • Blann, A.D.1
  • 109
    • 34548819350 scopus 로고    scopus 로고
    • Platelet and leukocyte activation, atherosclerosis and inflammation in European and South Asian men
    • Dotsenko O, et al. Platelet and leukocyte activation, atherosclerosis and inflammation in European and South Asian men. J Thromb Haemost 2007; 5: 2036–2042
    • (2007) J Thromb Haemost , vol.5 , pp. 2036-2042
    • Dotsenko, O.1
  • 110
    • 84880928455 scopus 로고    scopus 로고
    • Differential impact of inflammation on six laboratory assays measuring residual arachidonic acid-inducible platelet reactivity during dual antiplatelet therapy
    • Gremmel T, et al. Differential impact of inflammation on six laboratory assays measuring residual arachidonic acid-inducible platelet reactivity during dual antiplatelet therapy. J Atheroscler Thromb 2013; 20: 630–645
    • (2013) J Atheroscler Thromb , vol.20 , pp. 630-645
    • Gremmel, T.1
  • 111
    • 84884749444 scopus 로고    scopus 로고
    • Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: A randomized multicenter study
    • Karolczak K, et al. Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study. Pharmacol Res 2013; 74: 7–22
    • (2013) Pharmacol Res , vol.74 , pp. 7-22
    • Karolczak, K.1
  • 112
    • 84877032103 scopus 로고    scopus 로고
    • Reduced antiplatelet effect of aspirin is associated with lowgrade inflammation in patients with coronary artery disease
    • Larsen SB, et al. Reduced antiplatelet effect of aspirin is associated with lowgrade inflammation in patients with coronary artery disease. Thromb Haemost 2013; 109: 920–929
    • (2013) Thromb Haemost , vol.109 , pp. 920-929
    • Larsen, S.B.1
  • 113
    • 33646238447 scopus 로고    scopus 로고
    • Reduced blood platelet sensitivity to aspirin in coronary artery disease: Are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
    • Markuszewski L, et al. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin? Basic Clin Pharmacol Toxicol 2006; 98: 503–509
    • (2006) Basic Clin Pharmacol Toxicol , vol.98 , pp. 503-509
    • Markuszewski, L.1
  • 114
    • 84865272298 scopus 로고    scopus 로고
    • Markers of endothelial and platelet activation are associated with high on-aspirin platelet reactivity in patients with stable coronary artery disease
    • Pettersen AA, et al. Markers of endothelial and platelet activation are associated with high on-aspirin platelet reactivity in patients with stable coronary artery disease. Thromb Res 2012; 130: 424–428
    • (2012) Thromb Res , vol.130 , pp. 424-428
    • Pettersen, A.A.1
  • 115
    • 42249102444 scopus 로고    scopus 로고
    • C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor alpha, on human monocytes
    • Hanriot D, et al. C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor alpha, on human monocytes. Thromb Haemost 2008; 99: 558–569
    • (2008) Thromb Haemost , vol.99 , pp. 558-569
    • Hanriot, D.1
  • 116
    • 0034681947 scopus 로고    scopus 로고
    • Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: Relationship with age, sex, and hormone replacement treatment
    • Nakagomi A, et al. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. Circulation 2000; 101: 1785–1791
    • (2000) Circulation , vol.101 , pp. 1785-1791
    • Nakagomi, A.1
  • 117
    • 57649176643 scopus 로고    scopus 로고
    • The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients
    • Gori AM, et al. The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients. Atherosclerosis 2009; 202: 255–262
    • (2009) Atherosclerosis , vol.202 , pp. 255-262
    • Gori, A.M.1
  • 118
    • 67649549963 scopus 로고    scopus 로고
    • Elevations in soluble CD40 ligand in patients with high platelet aggregability undergoing percutaneous coronary intervention
    • Obradovic SD, et al. Elevations in soluble CD40 ligand in patients with high platelet aggregability undergoing percutaneous coronary intervention. Blood Coagul Fibrinolysis 2009; 20: 283–289
    • (2009) Blood Coagul Fibrinolysis , vol.20 , pp. 283-289
    • Obradovic, S.D.1
  • 119
    • 61649124757 scopus 로고    scopus 로고
    • The link between heightened thrombogenicity and inflammation: Pre-procedure characterisation of the patient at high risk for recurrent events after stenting
    • Gurbel PA, et al. The link between heightened thrombogenicity and inflammation: pre-procedure characterisation of the patient at high risk for recurrent events after stenting. Platelets 2009; 20: 97–104
    • (2009) Platelets , vol.20 , pp. 97-104
    • Gurbel, P.A.1
  • 120
    • 0142091359 scopus 로고    scopus 로고
    • Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling
    • Prasad KS, et al. Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci USA 2003; 100: 12367–12371
    • (2003) Proc Natl Acad Sci USA , vol.100 , pp. 12367-12371
    • Prasad, K.S.1
  • 121
    • 0037162340 scopus 로고    scopus 로고
    • Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: Effects of statin therapy
    • Cipollone F, et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002; 106: 399–402
    • (2002) Circulation , vol.106 , pp. 399-402
    • Cipollone, F.1
  • 122
    • 39849088945 scopus 로고    scopus 로고
    • Relationship between the serum sCD40L level and aspirinresistant platelet aggregation in patients with stable coronary artery disease
    • Pamukcu B, et al. Relationship between the serum sCD40L level and aspirinresistant platelet aggregation in patients with stable coronary artery disease. Circ J 2008; 72: 61–66
    • (2008) Circ J , vol.72 , pp. 61-66
    • Pamukcu, B.1
  • 123
    • 34548090571 scopus 로고    scopus 로고
    • Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes
    • Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 2007; 35: 1687–1693
    • (2007) Drug Metab Dispos , vol.35 , pp. 1687-1693
    • Aitken, A.E.1    Morgan, E.T.2
  • 124
    • 78649732206 scopus 로고    scopus 로고
    • Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment
    • Bernlochner I, et al. Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. Thromb Haemost 2010; 104: 1193–1200
    • (2010) Thromb Haemost , vol.104 , pp. 1193-1200
    • Bernlochner, I.1
  • 125
    • 78649649127 scopus 로고    scopus 로고
    • Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: Prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions
    • Geisler T, et al. Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions. Clin Res Cardiol 2010; 99: 743–752
    • (2010) Clin Res Cardiol , vol.99 , pp. 743-752
    • Geisler, T.1
  • 126
    • 77958466789 scopus 로고    scopus 로고
    • Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease
    • Muller K, et al. Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease. Atherosclerosis 2010; 213: 256–262
    • (2010) Atherosclerosis , vol.213 , pp. 256-262
    • Muller, K.1
  • 127
    • 51449118219 scopus 로고    scopus 로고
    • Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel
    • Ang L, et al. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol 2008; 52: 1052–1059
    • (2008) J am Coll Cardiol , vol.52 , pp. 1052-1059
    • Ang, L.1
  • 128
    • 70449442585 scopus 로고    scopus 로고
    • Enhanced post-clopidogrel platelet reactivity in diabetic patients is independently related to plasma fibrinogen level but not to glycemic control
    • Gaborit B, et al. Enhanced post-clopidogrel platelet reactivity in diabetic patients is independently related to plasma fibrinogen level but not to glycemic control. J Thromb Haemost 2009; 7: 1939–1941
    • (2009) J Thromb Haemost , vol.7 , pp. 1939-1941
    • Gaborit, B.1
  • 129
    • 0036714323 scopus 로고    scopus 로고
    • Inhibition of ADP-induced P-selectin expression and plateletleukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin
    • Storey RF, et al. Inhibition of ADP-induced P-selectin expression and plateletleukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost 2002; 88: 488–494
    • (2002) Thromb Haemost , vol.88 , pp. 488-494
    • Storey, R.F.1
  • 130
    • 24944457299 scopus 로고    scopus 로고
    • Clopidogrel inhibits platelet-leukocyte adhesion and platelet- dependent leukocyte activation
    • Evangelista V, et al. Clopidogrel inhibits platelet-leukocyte adhesion and platelet- dependent leukocyte activation. Thromb Haemost 2005; 94: 568–577
    • (2005) Thromb Haemost , vol.94 , pp. 568-577
    • Evangelista, V.1
  • 131
    • 33644775853 scopus 로고    scopus 로고
    • Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease
    • Angiolillo DJ, et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 2006; 55: 780–784
    • (2006) Diabetes , vol.55 , pp. 780-784
    • Angiolillo, D.J.1
  • 132
    • 57649176643 scopus 로고    scopus 로고
    • The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients
    • Gori AM, et al. The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients. Atherosclerosis 2009; 202: 255–262
    • (2009) Atherosclerosis , vol.202 , pp. 255-262
    • Gori, A.M.1
  • 133
    • 84865112417 scopus 로고    scopus 로고
    • High leukocyte count and interleukin-10 predict high ontreatment- platelet-reactivity in patients treated with clopidogrel
    • Osmancik P, et al. High leukocyte count and interleukin-10 predict high ontreatment- platelet-reactivity in patients treated with clopidogrel. J Thromb Thrombolysis 2012; 33: 349–354
    • (2012) J Thromb Thrombolysis , vol.33 , pp. 349-354
    • Osmancik, P.1
  • 134
    • 84880918511 scopus 로고    scopus 로고
    • Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis
    • Everett BM, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013; 166: 199–207
    • (2013) Am Heart J , vol.166 , pp. 199-207
    • Everett, B.M.1
  • 135
    • 80053644777 scopus 로고    scopus 로고
    • Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: Rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
    • Ridker PM, et al. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011; 162: 597–605
    • (2011) Am Heart J , vol.162 , pp. 597-605
    • Ridker, P.M.1
  • 136
    • 21844451117 scopus 로고    scopus 로고
    • C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: The cardiovascular health study
    • Cushman M, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 2005; 112: 25–31
    • (2005) Circulation , vol.112 , pp. 25-31
    • Cushman, M.1
  • 137
    • 0035824178 scopus 로고    scopus 로고
    • Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: Effects of an early invasive or noninvasive strategy
    • Lindmark E, et al. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. J Am Med Assoc 2001; 286: 2107–2113
    • (2001) J am Med Assoc , vol.286 , pp. 2107-2113
    • Lindmark, E.1
  • 138
    • 3042756855 scopus 로고    scopus 로고
    • Serum myeloperoxidase levels independently predict endothelial dysfunction in humans
    • Vita JA, et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 2004; 110: 1134–1139
    • (2004) Circulation , vol.110 , pp. 1134-1139
    • Vita, J.A.1
  • 139
    • 38449115330 scopus 로고    scopus 로고
    • Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes
    • Ndrepepa G, et al. Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. Eur J Clin Invest 2008; 38: 90–96
    • (2008) Eur J Clin Invest , vol.38 , pp. 90-96
    • Ndrepepa, G.1
  • 140
    • 45349099743 scopus 로고    scopus 로고
    • Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: Myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18
    • Morrow DA, et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 2008; 29: 1096–1102
    • (2008) Eur Heart J , vol.29 , pp. 1096-1102
    • Morrow, D.A.1
  • 141
    • 79955765430 scopus 로고    scopus 로고
    • Increased levels of leukocyte-derived MMP-9 in patients with stable angina pectoris
    • Jonsson S, et al. Increased levels of leukocyte-derived MMP-9 in patients with stable angina pectoris. PLoS One 2011; 6: e19340
    • (2011) Plos One , vol.6
    • Jonsson, S.1
  • 142
    • 0037312548 scopus 로고    scopus 로고
    • Matrix metalloproteinases and coronary artery diseases
    • Ikeda U, Shimada K. Matrix metalloproteinases and coronary artery diseases. Clin Cardiol 2003; 26: 55–59
    • (2003) Clin Cardiol , vol.26 , pp. 55-59
    • Ikeda, U.1    Shimada, K.2
  • 143
    • 33847060059 scopus 로고    scopus 로고
    • Matrix metalloproteinases in premature coronary atherosclerosis: Influence of inhibitors, inflammation, and genetic polymorphisms
    • Nanni S, et al. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms. Transl Res 2007; 149: 137–144
    • (2007) Transl Res , vol.149 , pp. 137-144
    • Nanni, S.1
  • 144
    • 80053341923 scopus 로고    scopus 로고
    • Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)): A review
    • Silva IT, et al. Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)): a review. Lipids Health Dis 2011; 10: 170
    • (2011) Lipids Health Dis , vol.10
    • Silva, I.T.1
  • 145
    • 54049152760 scopus 로고    scopus 로고
    • Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque
    • Serruys PW, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008; 118: 1172–1182
    • (2008) Circulation , vol.118 , pp. 1172-1182
    • Serruys, P.W.1
  • 146
    • 36048962679 scopus 로고    scopus 로고
    • Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease
    • Sabatine MS, et al. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 2007; 27: 2463–2469
    • (2007) Arterioscler Thromb Vasc Biol , vol.27 , pp. 2463-2469
    • Sabatine, M.S.1
  • 147
    • 84868275575 scopus 로고    scopus 로고
    • Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients
    • Maiolino G, et al. Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients. PLoS One 2012; 7: e48171
    • (2012) Plos One , vol.7
    • Maiolino, G.1
  • 148
    • 46349094873 scopus 로고    scopus 로고
    • Lipoprotein-associated phospholipase A2: An independent predictor of coronary artery disease events in primary and secondary prevention
    • Anderson JL. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol 2008; 101: 23F-33F.
    • (2008) Am J Cardiol , vol.101
    • Anderson, J.L.1
  • 149
    • 44649197216 scopus 로고    scopus 로고
    • Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (recurrence and inflammation in the acute coronary syndromes) study
    • Bogaty P, et al. Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (recurrence and inflammation in the acute coronary syndromes) study. J Am Coll Cardiol 2008; 51: 2339–2346
    • (2008) J am Coll Cardiol , vol.51 , pp. 2339-2346
    • Bogaty, P.1
  • 150
    • 77649223536 scopus 로고    scopus 로고
    • Early C-reactive protein in the prediction of long-term outcomes after acute coronary syndromes: A meta-analysis of longitudinal studies
    • He LP, et al. Early C-reactive protein in the prediction of long-term outcomes after acute coronary syndromes: a meta-analysis of longitudinal studies. Heart 2010; 96: 339–346
    • (2010) Heart , vol.96 , pp. 339-346
    • He, L.P.1
  • 151
    • 84865357032 scopus 로고    scopus 로고
    • Prognostic markers in young patients with premature coronary heart disease
    • van Loon JE, et al. Prognostic markers in young patients with premature coronary heart disease. Atherosclerosis 2012; 224: 213–217
    • (2012) Atherosclerosis , vol.224 , pp. 213-217
    • Van Loon, J.E.1
  • 152
    • 77950558969 scopus 로고    scopus 로고
    • Plasma calprotectin predicts mortality in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention
    • Jensen LJ, et al. Plasma calprotectin predicts mortality in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J Interv Cardiol 2010; 23: 123–129.
    • (2010) J Interv Cardiol , vol.23 , pp. 123-129
    • Jensen, L.J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.